



Rasha Eltanamly M.D. Professor of Ophthalmology, Cairo University



### **Role of Laser in Angle Closure Glaucoma**

- Conventional
  - Laser Pl
  - Laser iridoplasty
  - CPC

- Unconventional
  - SLT
  - CPC for APAC



- Indications
  - APAC
  - Fellow eye of APAC
  - Narrow angle of PACS
  - PACG
  - Miscellaneous PIS, PDG, phacomorphic, aq. misdirection





1. Can LPI resolve APAC?

2. Is LPI of value in PACS?

3. Does LPI prevent progression of PAC/G?



#### 1. Can LPI resolve APAC?

Am J Ophthalmol, 2001 Jan;131(1):7-12.

Acute primary angle-closure: long-term intraocular pressure outcome in Asian eyes.

Aung T<sup>1</sup>, Ang LP, Chan SP, Chew PT.

Eye (2019) 33:110-119 https://doi.org/10.1038/s41433-018-0278-x

**REVIEW ARTICLE** 

Resolution of attack in 110/111 58.1% elevated IOP & ttt at 5yr FU 32.7% needed trab

Acute primary angle closure-treatment strategies, evidences and economical considerations

Poemen P. Chan<sup>1,2</sup> · Jason C. Pang<sup>1</sup> · Clement C. Tham<sup>1,2,3</sup>

#### 2. Is LPI of value in PACS?

#### Longitudinal Changes of Angle Configuration 2 in Primary Angle-Closure Suspects

The Zhongshan Angle-Closure Prevention Trial

Lancet, 2019 Apr 20;393(10181):1609-1618. doi: 10.1016/S0140-6736(18)32607-2. Epub 2019 Mar 14.

Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial.

He M<sup>1</sup>, Jiang Y<sup>2</sup>, Huang S<sup>3</sup>, Chang DS<sup>4</sup>, Munoz B<sup>4</sup>, Aung T<sup>5</sup>, Foster PJ<sup>6</sup>, Friedman DS<sup>4</sup>.

EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY 2019 RCT 889 72m follow up Limited benefit LPI NOT recommended

#### 3. Does LPI prevent progression of PAC/G?

# PROTECTIVE AGAINST PAC, PACG Chronic Angle-closure with Glav Damage

Long-term Clinical Course in a N Population and Comparison with

an Population

Mohamad Rosman, MRCSEd (Ophth), MMed (Ophth), 1-2 Tin Aung, FRCS (Ed), FRCOphth,<sup>1</sup> Leonard P. K. Ang, FRCS (Ed),<sup>1</sup> Paul T. K. Chew, FRCS (Ed), FRCOphth,<sup>1,3</sup> Jeffrey M. Liebmann, MD, FACS,<sup>4,5</sup> Robert Ritch, FACS, FRCOphth<sup>4,5</sup>

Conclusions: Despite the presence of a patent LPI, most eyes with CACG presenting with elevated IOP and having both optic disc and visual field damage in both populations required further treatment to control IOP. Results in the American population are similar to that reported in Asian patients. Ophthalmology 2002;109: 2227–2231 © 2002 by the American Academy of Ophthalmology.

Machine	Nd:YAG OR Argon
Lens	Abraham
Follow u	р
Techniqu	le
	Site: crypt
	Peripheral 1/3
	200-500 μ
YAG	4-8mJ
	fixed spot size
	pulse 1-3

End point



- Complications
  - IOP spike
  - Hyphema
  - Inflammation
  - Focal cataract
  - Visual symptoms (haloes, glare, diplopia)
  - Corneal decompensation



## Laser Iridoplasty

 low energy burns applied to the peripheral iris to widen the AC angle and/or break PAS



EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY • Indications

- Failure of/initial ttt in APAC
- Initial ttt of PACD
- PIS
- Phacomorphic AC
- Contraction burns
  - 500 µm spot size
  - 0.5–0.7 s duration
  - Power 240 mW
  - 24 spots over 360°

### Laser Iridoplasty

#### • For plateau iris

8 Review
BMJ Open Ophthalmology Systematic review

Hugo Bourdon,<sup>61,2</sup> Vittoria Aragno,<sup>1,2</sup> Christophe Baudouin,<sup>1,3</sup> Antoine Labbé<sup>1,3</sup>

> Ophthalmology. 2004 Jan;111(1):104-8. doi: 10.1016/j.ophtha.2003.05.001.

Long-term success of argon laser peripheral iridoplasty in the management of plateau iris syndrome

Robert Ritch <sup>1</sup>, Clement C Y Tham, Dennis S C Lam

EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY Decrease IOP & meds Widen angle No current evidence of longterm efficacy (2019)

23 eyes FU 79 m The angle in 20 eyes (87.0%) remained open. Gradual re-closure of angle in 3 eyes (reopened with single repeat)

### **SLT for ACG**

Comparative Study > J Glaucoma. 2016 Mar;25(3):e253-8. doi: 10.1097/UG.00000000000282.

Selective Laser Trabeculoplasty in Primary Angleclosure Glaucoma After Laser Peripheral Iridotomy: A Case-Control Study

Research

#### Original Investigation | CLINICAL TRIAL

#### Efficacy of Selective Laser Trabeculoplasty in Primary Angle-Closure Glaucoma A Randomized Clinical Trial

Arun Narayanaswamy, MMed; Christopher K. Leung, FCOphth; Donny V. Istiantoro, SpM; Shamira A. Perera, FRCOphth; Ching-Lin Ho, FRCS(Ed); Monisha E. Nongpiur, MD; Mani Baskaran, DNB; Hla M. Htoon, PhD; Tina T. Wong, FRCOphth; David Goh, FRCOphth; Daniel H. Su, FRCS(Ed); Michael Belkin, MD; Tin Aung, FRCOphth

EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY Postop IOP reduction in the PAC/PACG and POAG was not significantly different (P=0.66).

The success rate; IOP drop of 20% or more, or stopping of 1 or more medications was 85% in the PAC/PACG group and 80% in the POAG group (P=0.47).

96 patients SLT vs PGA 6 m NO sig diff in mean reduction (4 vs 4.2) & % reduction (16.9 vs 18.5)

### **SLT for ACG**



ARVO Annual Meeting Abstract | June 2021

#### Angle-Closure Glaucoma Treated with Selective Laser Trabeculoplasty. Report of Efficacy and Safety after One-Year.

Sara Aurora Garcia y Otero Sánchez; Jose A Paczka; fabiola Garcia y Otero; Julio Moreno - Nava; Luz

Abstract Issue 2021

America Paczka-Giorgi

**OPEN ACCESS** 

June 2021 Volume 62, Issue 8 + Author Affiliations & Notes

Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2573. doi:

Eye (2018) 32:1710-1716 https://doi.org/10.1038/s41433-018-0165-5

ARTICLE

The ROYAL COLLEGE o OPHTHALMOLOGIST

Efficacy of selective laser trabeculoplasty in primary angle closure disease

Srishti Raj<sup>1</sup> · Basavraj Tigari<sup>1</sup> · T. T. Faisal<sup>1</sup> · Natasha Gautam<sup>1</sup> · Sushmita Kaushik<sup>1</sup> · Parul Ichhpujani<sup>2</sup> · Surinder S. Pandav<sup>1</sup> · Jagat Ram<sup>1</sup>

#### FOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY

26 patients prior deep AC Sig. drop of anti glaucoma meds and Mean IOP Success rate 65%

34 patients prior deep AC Post-SIT IOP reduction 9 -46% at 1 year. Mean IOP in both PAC and PACG groups was comparable at all visits

## **Cyclophotocoagulation for ACG**

### Indications

- CACG with uncontrolled high IOP
- Patients refusing/unfit for surgery
- 1750 -2000 mW, 2 ms, pop, 270<sup>o</sup>, 6 shots
- Side effects
  - Uveitis
  - Hyphema
  - Hypotony/ phthisis
  - Scarred conj



## **Cyclophotocoagulation for ACG**

### • In managing unresolved APAC

Liu et al. BMC Ophthalmology (2020) 20:209 https://doi.org/10.1186/s12886-020-01493-0

**BMC Ophthalmology** 

#### **RESEARCH ARTICLE**

Transscleral cyclophotocoagulation followed by cataract surgery: a novel protocol to treat refractory acute primary angle closure

Wei Liu<sup>1,2†</sup>, Luning Qin<sup>1†</sup>, Chenjia Xu<sup>1</sup>, Dandan Huang<sup>1</sup>, Ruru Guo<sup>1</sup>, Jian Ji<sup>1\*</sup>0 and Nomdo M. Jansonius<sup>2</sup>

#### EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY



13 prospective case series Compared to phacotrab CPC 2000mW, 2000ms,20, inferior IOP drop from 51.5 to to 16.4 mmHg 1 day post CPC No diff in IOP, BCVA, meds, ACD, angle opening at 6 m



### Take home message

- Lens removal is the mainstay treatment of ACD
- Role of prophylactic PI is limited
- SLT can be used in eyes with visible TM with good outcome, yet no long term results
- CPC may be used in unresolved acute attacks as a preparatory step before surgery